Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:FNCH NASDAQ:GLMD NASDAQ:GOVX NASDAQ:PHIO On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeFNCHFinch Therapeutics Group$7.30$7.98$2.00▼$16.10$11.72M1.185,025 shsN/AGLMDGalmed Pharmaceuticals$0.69-5.0%$0.62$0.41▼$2.34$3.98M0.73144,291 shs153,631 shsGOVXGeoVax Labs$2.10-5.0%$1.61$0.96▼$34.75$7.68M3.6214.76 million shs659,099 shsPHIOPhio Pharmaceuticals$1.12-0.9%$1.19$0.81▼$4.19$13.13M0.82134,282 shs100,509 shs(Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceFNCHFinch Therapeutics Group0.00%-2.01%-10.43%-44.91%-46.32%GLMDGalmed Pharmaceuticals-4.96%+9.70%+21.01%+17.61%-52.34%GOVXGeoVax Labs-4.98%-39.83%+82.61%+22.81%-91.92%PHIOPhio Pharmaceuticals-0.88%+3.70%-1.75%-2.61%-45.37%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeFNCHFinch Therapeutics Group$7.30$7.98$2.00▼$16.10$11.72M1.185,025 shsN/AGLMDGalmed Pharmaceuticals$0.69-5.0%$0.62$0.41▼$2.34$3.98M0.73144,291 shs153,631 shsGOVXGeoVax Labs$2.10-5.0%$1.61$0.96▼$34.75$7.68M3.6214.76 million shs659,099 shsPHIOPhio Pharmaceuticals$1.12-0.9%$1.19$0.81▼$4.19$13.13M0.82134,282 shs100,509 shs(Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceFNCHFinch Therapeutics Group0.00%-2.01%-10.43%-44.91%-46.32%GLMDGalmed Pharmaceuticals-4.96%+9.70%+21.01%+17.61%-52.34%GOVXGeoVax Labs-4.98%-39.83%+82.61%+22.81%-91.92%PHIOPhio Pharmaceuticals-0.88%+3.70%-1.75%-2.61%-45.37%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceFNCHFinch Therapeutics Group 0.00N/AN/AN/AGLMDGalmed Pharmaceuticals 1.00SellN/AN/AGOVXGeoVax Labs 1.50Reduce$150.007,042.86% UpsidePHIOPhio Pharmaceuticals 2.00Hold$14.001,150.00% UpsideCurrent Analyst Ratings BreakdownLatest GLMD, PHIO, GOVX, and FNCH Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/21/2026GLMDGalmed Pharmaceuticals Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)4/21/2026GOVXGeoVax Labs Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)4/21/2026PHIOPhio Pharmaceuticals Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)4/16/2026GOVXGeoVax Labs D. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingHold(Data available from 6/3/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookFNCHFinch Therapeutics GroupN/AN/AN/AN/A$14.25 per shareN/AGLMDGalmed PharmaceuticalsN/AN/AN/AN/A$2.88 per shareN/AGOVXGeoVax Labs$2.49M2.93N/AN/A$2.21 per share0.95PHIOPhio PharmaceuticalsN/AN/AN/AN/A$1.87 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateFNCHFinch Therapeutics Group-$74.75M-$8.82N/AN/AN/AN/A-69.14%-26.92%N/AGLMDGalmed Pharmaceuticals-$10.31M-$1.24N/AN/AN/AN/A-29.43%-26.00%7/30/2026 (Estimated)GOVXGeoVax Labs-$21.47M-$19.12N/AN/AN/AN/A-709.52%-399.33%7/27/2026 (Estimated)PHIOPhio Pharmaceuticals-$8.70M-$1.38N/AN/AN/AN/A-77.34%-70.87%8/13/2026 (Estimated)Latest GLMD, PHIO, GOVX, and FNCH EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2026Q4 2025GOVXGeoVax Labs-$3.8421-$2.62+$1.2221-$2.62N/AN/A5/7/2026Q1 2026PHIOPhio Pharmaceuticals-$0.24-$0.34-$0.10-$0.34N/AN/A4/15/2026Q4 2025GOVXGeoVax LabsN/A$1.85N/A$1.85N/AN/A3/5/2026Q4 2025PHIOPhio Pharmaceuticals-$0.34-$0.15+$0.19-$0.15N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthFNCHFinch Therapeutics GroupN/AN/AN/AN/AN/AGLMDGalmed PharmaceuticalsN/AN/AN/AN/AN/AGOVXGeoVax LabsN/AN/AN/AN/AN/APHIOPhio PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioFNCHFinch Therapeutics GroupN/A3.873.87GLMDGalmed PharmaceuticalsN/A6.556.55GOVXGeoVax LabsN/A1.061.06PHIOPhio PharmaceuticalsN/A18.3218.32Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipFNCHFinch Therapeutics Group21.77%GLMDGalmed Pharmaceuticals76.14%GOVXGeoVax Labs6.09%PHIOPhio Pharmaceuticals57.31%Insider OwnershipCompanyInsider OwnershipFNCHFinch Therapeutics Group44.90%GLMDGalmed Pharmaceuticals19.80%GOVXGeoVax Labs0.69%PHIOPhio Pharmaceuticals0.89%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableFNCHFinch Therapeutics Group1901.61 million885,000No DataGLMDGalmed Pharmaceuticals205.48 million4.39 millionNot OptionableGOVXGeoVax Labs103.47 million3.45 millionNot OptionablePHIOPhio Pharmaceuticals1011.62 million11.51 millionNot OptionableGLMD, PHIO, GOVX, and FNCH HeadlinesRecent News About These CompaniesPhio Pharmaceuticals to Participate in the Renmark Financial Communications Live Virtual Non-Deal Roadshow SeriesMay 27, 2026 | tennessean.comTPhio Pharmaceuticals Corp.: Phio Pharmaceuticals Reports First Quarter 2026 Financial Results and Business UpdateMay 8, 2026 | finanznachrichten.dePhio Pharmaceuticals Reports First Quarter 2026 Financial Results and Business UpdateMay 7, 2026 | newsfilecorp.comNPhio Pharmaceuticals Corp.: Phio Pharmaceuticals Announces "Nobel Prize Winning Science Takes on Skin Cancer" in a Fireside Chat with Force Family Office on Wednesday, April 15 ...April 14, 2026 | finanznachrichten.dePhio Pharmaceuticals Announces "Nobel Prize Winning Science Takes on Skin Cancer" in a Fireside Chat with Force Family Office on Wednesday, April 15, 2026April 13, 2026 | newsfilecorp.comNPhio Pharmaceuticals Announces Presentation at Centri Capital Conference on April 14, 2026April 9, 2026 | finance.yahoo.comPyramid Pharma Services Announces Drug Product Manufacturing Agreement for Phio Pharmaceuticals’ Lead Oncology CandidateApril 8, 2026 | jsonline.comJPhio Pharmaceuticals Corp.: Phio Pharmaceuticals Announces Agreement with U.S. cGMP Manufacturing Source for Drug Product, PH-762March 31, 2026 | finanznachrichten.dePhio Pharmaceuticals Announces Agreement with U.S. cGMP Manufacturing Source for Drug Product, PH-762March 30, 2026 | newsfilecorp.comNPhio Pharmaceuticals Announces American Academy of Dermatology 2026 Presentation Featuring Clinical Study Results from Study of PH-762 for Cutaneous Carcinoma Underscoring ...March 23, 2026 | finance.yahoo.comPhio Pharmaceuticals Announces American Academy of Dermatology 2026 Presentation Featuring Clinical Study Results from Study of PH-762 for Cutaneous Carcinoma Underscoring Clinical Pipeline AdvancementMarch 23, 2026 | newsfilecorp.comNPhio Pharmaceuticals Corp.: Phio Pharmaceuticals Announces "A Groundbreaking Approach to Treating Skin Cancer" in a Fireside Chat with Force Family OfficeMarch 16, 2026 | finanznachrichten.dePhio Pharmaceuticals Announces "A Groundbreaking Approach to Treating Skin Cancer" in a Fireside Chat with Force Family OfficeMarch 16, 2026 | newsfilecorp.comNB2i Digital Highlights Life Sciences Virtual Investor Forum as a Featured ConferenceMarch 11, 2026 | finance.yahoo.comPhio Pharmaceuticals Corp.: Phio Pharmaceuticals to Present at the Life Sciences Investor Forum on March 12, 2026, 11 AM EDTMarch 10, 2026 | finanznachrichten.dePhio Pharmaceuticals to Present at the Life Sciences Investor Forum on March 12, 2026 11 AM EDTMarch 10, 2026 | financialpost.comFPhio Pharmaceuticals to Present at the Life Sciences Investor Forum on March 12, 2026 11 AM EDTMarch 10, 2026 | globenewswire.comPhio Pharmaceuticals to Present at the Life Sciences Investor Forum on March 12, 2026 11 AM EDTMarch 10, 2026 | financialpost.comFPhio Pharmaceuticals to Present at the Life Sciences Investor Forum on March 12, 2026 11 AM EDTMarch 10, 2026 | globenewswire.comPhio Pharmaceuticals to Present at the Life Sciences Investor Forum on March 12, 2026, 11 AM EDTMarch 10, 2026 | newsfilecorp.comNNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesThe Real SpaceX Play: 5 Chip Stocks Powering the IPO Before It LaunchesBy Bridget Bennett | May 4, 2026SpaceX Gets the Attention, But These 4 Stocks Could Get the ReturnsBy Bridget Bennett | May 25, 2026Apple Talks Just Changed Everything for IntelBy Sam Quirke | May 6, 20263 Energy Stocks to Buy and 2 to Avoid as AI Power Demand ExplodesBy Bridget Bennett | May 4, 2026Is Co-Diagnostics National Security’s Next Diagnostic Pick?By Jeffrey Neal Johnson | May 28, 2026GLMD, PHIO, GOVX, and FNCH Company DescriptionsFinch Therapeutics Group NASDAQ:FNCH$7.30 0.00 (0.00%) As of 06/1/2026Finch Therapeutics Group, Inc., a clinical-stage microbiome therapeutics company, develops a novel class of orally administered biological drugs in the United States. The company develops FIN-211, a microbiome candidate designed to address the gastrointestinal and behavioral symptoms of autism spectrum disorder; and FIN-524 for the prevention, diagnosis, theragnosis or treatment of diseases in humans, including ulcerative colitis; FIN-525 for the treatment of Crohn's disease; and other microbiome product candidates. The company has collaboration and license agreements with Takeda Pharmaceutical Company Limited; and license agreements with Skysong Innovations LLC, OpenBiome, Arizona State University, and University of Minnesota. Finch Therapeutics Group, Inc. was incorporated in 2014 and is based in Boston, Massachusetts.Galmed Pharmaceuticals NASDAQ:GLMD$0.69 -0.04 (-4.96%) Closing price 06/2/2026 04:00 PM EasternExtended Trading$0.69 +0.00 (+0.27%) As of 05:37 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Galmed Pharmaceuticals Ltd., a biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. It develops Aramchol, an oral therapy, which is in Phase III study for the treatment of non-alcoholic steato-hepatitis (NASH) in patients with overweight or obesity and who are pre-diabetic or type-II-diabetes mellitus. The company also evaluates Aramchol through ARRIVE Study, a Phase IIa clinical trial with HIV-associated non-alcoholic fatty liver disease and lipodystrophy. In addition, it engages in the development of Amilo-5MER, a 5 amino acid synthetic peptide methionine, threonine, alanine, aspartic acid, and valine. It has a license agreement with Samil Pharma. Co., Ltd. for the commercialization of Aramchol in the Republic of Korea; and a collaboration agreement with OnKai for its AI platform. Galmed Pharmaceuticals Ltd. was founded in 2000 and is headquartered in Tel Aviv, Israel.GeoVax Labs NASDAQ:GOVX$2.10 -0.11 (-4.98%) Closing price 06/2/2026 04:00 PM EasternExtended Trading$2.09 -0.01 (-0.48%) As of 06:29 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.GeoVax Labs, Inc., a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and solid tumor cancers using modified vaccinia ankara virus-like particle vaccine platform. It is developing various preventive vaccines against (COVID-19), human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and Lassa, as well as therapeutic vaccines for HIV, chronic Hepatitis B infections, and solid tumor cancers. The company is developing GEO-CM04S1, a vaccine candidate that is in Phase 2 clinical trial for the treatment of preventive COVID-19; Gedeptin, a novel patented product/technology for the treatment of solid tumors, and Phase 1/2 clinical trial for the treatment of advanced head and neck squamous cell carcinoma; and GEO-CM02, a pan-coronavirus vaccine. In addition, it is developing GEO-ZM02, a vaccine candidate, which is in preclinical trial for the treatment of GEO-ZM02, a vaccine candidate, which is in preclinical trial for the treatment of Zika; GEO-MM02 treatment for malaria; other infectious disease vaccines for the treatment of fever viruses, such as Ebola, Sudan, and Marburg; GEO-LM01 for the treatment of Lassa fever. It has collaboration and partnership agreements with the National Institute of Allergy and Infectious Diseases of the National Institutes of Health; U.S. Department of Defense; Emory University; and the Burnet Institute. GeoVax Labs, Inc. was incorporated in 1988 and is headquartered in Smyrna, Georgia.Phio Pharmaceuticals NASDAQ:PHIO$1.12 -0.01 (-0.88%) Closing price 06/2/2026 04:00 PM EasternExtended Trading$1.12 0.00 (0.00%) As of 04:23 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Phio Pharmaceuticals Corp. engages in the development of immuno-oncology therapeutics in the United States. The company is developing PH-762, an INTASYL compound in Phase 1b dose-escalating clinical trials to reduce the expression of cell death protein 1 (PD-1), a protein that inhibits T cells' ability to kill cancer cells; and PH-762 treated double positive tumor infiltrating lymphocytes, which is in Phase 1 clinical trials to treat advanced melanoma and other advanced solid tumors. It is also developing PH-894, an INTASYL compound in IND enabling studies to silence BRD4, a protein that controls gene expression in both T cells and tumor cells, effecting the immune system and the tumor. The company was formerly known as RXi Pharmaceuticals Corporation and changed its name to Phio Pharmaceuticals Corp. in November 2018. Phio Pharmaceuticals Corp. was incorporated in 2011 and is based in Marlborough, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Marvell Stock Soars on NVIDIA's Trillion-Dollar Nod Dollar General Signals Reversal With 60% Rebound Potential Kohl's Stock Soars After Better-Than-Feared Quarter Credo Technologies Paved a Path to a $300 Price Point MGM Buyout: The House Doesn't Always Win Alphabet's $80 Billion Offering: Worrisome Dilution or AI Confidence? FirstCash Turns Pawn Into a Growth Machine HubSpot Just Crushed the Bear Case—Is a Bigger Rally Ahead? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
